NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

CDNA

Caredx Inc

Jun 24 • 10:18AM ET

19.18

Dollar change +0.23
Percentage change 1.24	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: NTRA ILMN FLGT GH EXAS TWST VRTX CRSP TXG QGEN

| Held by: ARKG VTI IWM XBI VXF VB IWN PBE IBB VBK

Index	RUT	P/E	16.65	EPS (ttm)	1.15	Insider Own	6.78%	Shs Outstand	55.46M	Perf Week	0.60%
Market Cap	1.07B	Forward P/E	116.27	EPS next Y	0.17	Insider Trans	-3.98%	Shs Float	51.90M	Perf Month	12.12%
Enterprise Value	867.55M	PEG	-	EPS next Q	-0.10	Inst Own	98.60%	Short Float	12.52%	Perf Quarter	-2.17%
Income	68.54M	P/S	3.08	EPS this Y	-137.81%	Inst Trans	6.03%	Short Ratio	6.14	Perf Half Y	-5.96%
Sales	346.42M	P/B	2.80	EPS next Y	146.92%	ROA	14.55%	Short Interest	6.50M	Perf YTD	-10.40%
Book/sh	6.84	P/C	4.63	EPS next 5Y	-11.41%	ROE	21.57%	52W High	34.84 -44.94%	Perf Year	37.32%
Cash/sh	4.15	P/FCF	53.01	EPS past 3/5Y	- -	ROIC	16.99%	52W Low	13.81 38.92%	Perf 3Y	-6.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.04% 21.31%	Gross Margin	66.92%	Volatility	2.00% 3.61%	Perf 5Y	-37.59%
Dividend TTM	-	EV/Sales	2.50	EPS Y/Y TTM	136.76%	Oper. Margin	-8.91%	ATR (14)	0.87	Perf 10Y	206.95%
Dividend Ex-Date	-	Quick Ratio	3.84	Sales Y/Y TTM	25.92%	Profit Margin	19.79%	RSI (14)	56.58	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.11	EPS Q/Q	41.89%	SMA20	2.95%	Beta	2.18	Target Price	29.00
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	17.54%	SMA50	8.77%	Rel Volume	0.31	Prev Close	18.95
Employees	650	LT Debt/Eq	0.06	Earnings	Apr 30 AMC	SMA200	-12.71%	Avg Volume	1.06M	Price	19.18
IPO	Jul 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.08% 0.40%	Trades		Volume	54,585	Change	1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-15-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$28 → $24
Aug-28-24	Initiated	Wells Fargo	Underweight	$28
Aug-19-24	Upgrade	BTIG Research	Neutral → Buy	$40
May-13-24	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-24	Upgrade	Craig Hallum	Hold → Buy	$15
Nov-09-23	Upgrade	Stephens	Equal-Weight → Overweight	$10
Aug-15-23	Upgrade	Raymond James	Mkt Perform → Outperform	$12
May-11-23	Downgrade	BTIG Research	Buy → Neutral
Mar-07-23	Downgrade	Stephens	Overweight → Equal-Weight	$19 → $9
Mar-03-23	Downgrade	Raymond James	Strong Buy → Mkt Perform
Mar-03-23	Downgrade	Craig Hallum	Buy → Hold	$26 → $9
Apr-25-22	Initiated	Stephens	Overweight	$50
Jul-20-21	Resumed	BTIG Research	Buy	$115
Jun-03-21	Initiated	Goldman	Buy	$95
Feb-26-21	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-30-20	Reiterated	H.C. Wainwright	Buy	$47 → $55
Oct-08-20	Reiterated	H.C. Wainwright	Buy	$45 → $47
Oct-02-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Aug-05-20	Reiterated	H.C. Wainwright	Buy	$37 → $40
Jun-26-20	Initiated	BTIG Research	Buy	$40

Show Previous Ratings

Jun-03-25 04:30PM	CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire) +10.67%
May-13-25 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-01-25 03:17AM	CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments (GuruFocus.com) -10.72%
Apr-30-25 08:39PM	CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript (Seeking Alpha) -6.89%
05:50PM	CareDx (CDNA) Tops Q1 Earnings Estimates (Zacks)
04:50PM	Loading…
04:50PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 07:05AM	CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-24-25 07:05AM	CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-21-25 04:01PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-08-25 07:05AM	CareDx to Report First Quarter 2025 Financial Results (Business Wire)
Apr-04-25 12:40PM	Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-11-25 07:05AM	CareDx Launches Two Expanded Indications for AlloSure Testing Services (Business Wire)
Feb-27-25 02:20AM	CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-25 07:00PM	CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:56PM	Loading…
04:56PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-25-25 10:39AM	CareDx Inc (CDNA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:05AM	CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict (Business Wire)
Feb-20-25 07:05AM	CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients (Business Wire) -5.34%
Feb-13-25 07:05AM	CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies (Business Wire)
Feb-11-25 07:05AM	CareDx to Report Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -8.43%
03:22AM	CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV) +11.16%
02:51PM	Final Trades: NRG Energy, MP Materials, CareDx and Applovin (CNBC TV)
Feb-05-25 09:55AM	Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect? (Zacks)
Jan-29-25 09:40AM	Is CareDx (CDNA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-28-25 08:19AM	CareDx (CDNA) Traded Down Due to Disappointing Quarterly Results (Insider Monkey)
Jan-24-25 08:35AM	Heres Why CareDx (CDNA) Traded Lower in Q4 (Insider Monkey)
Jan-15-25 03:50PM	Wells Fargo upgrades CareDx after a 30% pullback in stock (Investing.com)
03:43AM	Loading…
Jan-14-25 03:43AM	Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength? (Zacks) -12.05%
Jan-13-25 07:00AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results (Business Wire) +6.09%
Jan-06-25 09:35AM	Implied Volatility Surging for CareDx (CDNA) Stock Options (Zacks)
Dec-18-24 07:05AM	CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.86%
Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
07:00AM	CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (Business Wire)
Dec-03-24 09:40AM	Has CareDx (CDNA) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-29-24 10:46AM	Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA) (Insider Monkey)
Nov-25-24 09:55AM	Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know (Zacks)
Nov-15-24 09:35AM	After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA) (Zacks)
Nov-14-24 09:40AM	Are Medical Stocks Lagging CareDx (CDNA) This Year? (Zacks) -5.40%
Nov-12-24 07:05AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 09:04AM	Accelerated Testing Volume Lifted CareDx (CDNA) in Q3 (Insider Monkey)
Nov-05-24 01:03PM	Q3 2024 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-24 05:03PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance (Business Wire)
Oct-23-24 07:00AM	CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology (Business Wire)
Oct-21-24 07:00AM	CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting (Business Wire)
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in CareDx Inc Holdings (GuruFocus.com) -6.49%
Oct-16-24 08:17AM	CareDx Reports Strong Q3 2024 Revenue Growth (TipRanks)
Oct-15-24 06:00AM	CareDx Reports Preliminary Financial Results for Third Quarter 2024 (Business Wire) -15.84%
Oct-11-24 04:30PM	CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:35PM	CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... (GuruFocus.com) -12.42%
07:05AM	CareDx Appoints Jing Huang Chief Data and AI Officer (Business Wire)
Oct-08-24 04:05PM	CareDx to Host Investor Day on October 15, 2024 (Business Wire)
06:05AM	CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing (Business Wire)
Sep-13-24 08:35PM	CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:33PM	CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-12-24 07:01AM	CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer (Business Wire)
Aug-26-24 06:06AM	CareDx (CDNA) Surged Due to Positive Testing Volume Growth (Insider Monkey)
04:36AM	Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT) (Insider Monkey)
Aug-16-24 02:10PM	CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing (Business Wire) +16.40%
Aug-09-24 09:15AM	CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-07-24 12:00PM	CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Aug-06-24 03:58PM	CareDx, Inc (CDNA): Among the Best Organ Transplant and Diagnosis Stocks to Buy According to Hedge Funds? (Insider Monkey) +5.57%
Jul-31-24 08:00PM	Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics (Zacks) +6.56% +17.96%
06:05PM	CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:01PM	CareDx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance (Business Wire)
Jul-16-24 07:05AM	CareDx to Report Second Quarter 2024 Financial Results (Business Wire) +15.06%
Jun-03-24 07:05AM	Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients (Business Wire)
May-30-24 07:05AM	AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress (Business Wire)
May-29-24 08:05AM	CareDx Reiterates Position that it Does Not Infringe the 544 Patent, Injunction Motion is Irrelevant (Business Wire) -16.69%
07:05AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-16-24 04:05PM	Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies (Business Wire)
May-14-24 07:17AM	--Raymond James Downgrades CareDx to Market Perform From Outperform (MT Newswires)
May-13-24 10:12AM	Stephens Adjusts Price Target on CareDx to $18 From $15, Maintains Overweight Rating (MT Newswires)
May-10-24 02:26PM	CareDx Shares Rise After Q1 Results Beat Estimates (MT Newswires) +34.09%
02:21PM	CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance (GuruFocus.com)
11:46AM	CareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:00PM	CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +8.64%
05:32PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2024 Results (Business Wire)
May-07-24 09:15AM	CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-03-24 04:10PM	CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-24 04:05PM	CareDx to Report First Quarter 2024 Financial Results (Business Wire) +8.47% -5.37%
Apr-19-24 04:05PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-18-24 03:47AM	CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Apr-16-24 04:02PM	CareDx Appoints John W. Hanna as its New President and Chief Executive Officer (Business Wire) +5.48%
Apr-09-24 07:00AM	CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-01-24 08:40AM	How CareDx (CDNA) Stock Stands Out in a Strong Industry (Zacks)
Mar-11-24 04:10PM	CareDx Appoints Bryan Riggsbee to Its Board of Directors (Business Wire)
Feb-29-24 10:43AM	CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.47%
06:59AM	Q4 2023 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 07:00PM	CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:28PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:57PM	CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023 (GuruFocus.com)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 04:05PM	CareDx to Participate in the Raymond James & Associates 45th Annual Institutional Investors Conference (Business Wire) +6.39%

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valantine Hannah	Director	Jun 18 '25	Sale	19.16	10,570	202,566	38,994	Jun 23 04:30 PM
Maag Peter	Director	Jun 17 '25	Sale	19.24	10,000	192,420	318,846	Jun 20 04:30 PM
HANNAH VALANTINE	Director	Jun 18 '25	Proposed Sale	19.52	10,570	206,326		Jun 18 04:26 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Option Exercise	13.20	19,391	256,052	73,370	Jun 13 05:06 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Sale	19.90	19,391	385,918	53,979	Jun 13 05:06 PM
WILLIAM HAGSTROM	Director	Jun 11 '25	Proposed Sale	19.90	19,391	385,918		Jun 11 04:20 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Option Exercise	7.45	30,000	223,441	83,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Sale	17.45	30,000	523,413	53,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Proposed Sale	17.63	30,000	528,900		May 28 05:01 PM
COURNOYER CHRISTINE	Director	May 12 '25	Option Exercise	7.96	29,136	231,923	66,181	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Sale	15.96	29,136	465,022	37,045	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Proposed Sale	15.96	29,136	465,021		May 12 05:15 PM
Christine M. Cournoyer	Director	May 12 '25	Proposed Sale	15.36	12,000	184,320		May 12 05:10 PM
COURNOYER CHRISTINE	Director	May 06 '25	Sale	14.13	16,700	235,929	37,045	May 08 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	May 05 '25	Sale	14.70	2,688	39,514	121,350	May 07 04:38 PM
Christine M. Cournoyer	Director	May 06 '25	Proposed Sale	15.17	16,700	253,339		May 06 05:00 PM
Jeffrey Adam Novack	Officer	May 05 '25	Proposed Sale	15.00	2,688	40,320		May 05 04:39 PM
Maag Peter	Director	Apr 30 '25	Sale	17.23	13,281	228,796	316,743	May 02 04:49 PM
PETER MAAG	Director	Apr 30 '25	Proposed Sale	18.13	33,281	603,385		Apr 30 04:18 PM
Jain Abhishek	Chief Financial Officer	Apr 07 '25	Sale	17.72	265	4,696	337,418	Apr 09 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	Apr 07 '25	Sale	17.72	924	16,373	126,911	Apr 09 04:30 PM
Bickerstaff George	Director	Mar 10 '25	Sale	18.36	20,000	367,102	103,027	Mar 12 04:30 PM
GEORGE W BICKERSTAFF	Director	Mar 10 '25	Proposed Sale	18.36	20,000	367,102		Mar 10 05:03 PM
Novack Jeffrey Adam	Secretary and General Counsel	Feb 04 '25	Sale	23.30	3,512	81,829	104,677	Feb 05 04:30 PM
Jeffrey Adam Novack	Officer	Feb 04 '25	Proposed Sale	23.32	3,512	81,900		Feb 04 04:18 PM
Novack Jeffrey Adam	Secretary and General Counsel	Dec 04 '24	Sale	26.00	1,917	49,842	110,237	Dec 06 04:32 PM
Jeffrey Adam Novack	Officer	Dec 04 '24	Proposed Sale	24.96	1,917	47,848		Dec 04 04:42 PM
Maag Peter	Director	Nov 26 '24	Option Exercise	12.24	5,000	61,200	335,024	Dec 03 08:54 PM
Maag Peter	Director	Nov 26 '24	Sale	25.00	5,000	125,000	330,024	Dec 03 08:54 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 18 '24	Sale	21.77	5,534	120,477	113,377	Dec 03 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 25 '24	Sale	24.00	1,223	29,352	112,154	Dec 03 04:31 PM
PETER MAAG	Director	Nov 26 '24	Proposed Sale	24.11	5,000	120,550		Nov 26 04:25 PM
JEFFREY NOVACK	Officer	Nov 25 '24	Proposed Sale	23.13	1,223	28,288		Nov 25 04:45 PM
JEFFREY NOVACK	Officer	Nov 18 '24	Proposed Sale	21.17	5,534	117,155		Nov 18 05:11 PM
Bickerstaff George	Director	Nov 01 '24	Option Exercise	5.74	7,481	42,962	123,027	Nov 05 04:42 PM
Johnson Alexander L	See Remarks	Aug 20 '24	Option Exercise	23.48	39,466	926,662	324,449	Aug 22 05:15 PM
Johnson Alexander L	See Remarks	Aug 21 '24	Option Exercise	23.48	21,557	506,158	306,540	Aug 22 05:15 PM
Johnson Alexander L	See Remarks	Aug 20 '24	Sale	33.17	39,466	1,309,087	284,983	Aug 22 05:15 PM
Johnson Alexander L	See Remarks	Aug 21 '24	Sale	32.58	21,557	702,327	284,983	Aug 22 05:15 PM
Maag Peter	Director	Aug 20 '24	Option Exercise	7.96	26,708	212,596	365,576	Aug 22 04:43 PM
Maag Peter	Director	Aug 20 '24	Sale	33.04	35,552	1,174,493	330,024	Aug 22 04:43 PM
Johnson Alexander L	See Remarks	Aug 19 '24	Sale	33.55	34,231	1,148,335	284,983	Aug 21 04:38 PM
Johnson Alexander L	Officer	Aug 20 '24	Proposed Sale	33.00	61,023	2,013,759		Aug 20 06:25 PM
Johnson Alexander L	Officer	Aug 19 '24	Proposed Sale	33.55	34,231	1,148,355		Aug 20 06:21 PM
Maag Peter	Director	Aug 20 '24	Proposed Sale	33.51	35,552	1,191,478		Aug 20 05:13 PM

Open in Screener

BBIO

BridgeBio Pharma Inc

Jun 24 • 10:18AM ET

42.76

Dollar change +0.58
Percentage change 1.38	%

Healthcare • Biotechnology • USA • NASD

BBIO BridgeBio Pharma Inc daily Stock Chart

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI IWM VB XBI VXF VBK IBB IWO SCHA XT

Index	RUT	P/E	-	EPS (ttm)	-3.53	Insider Own	15.35%	Shs Outstand	189.83M	Perf Week	3.93%
Market Cap	8.12B	Forward P/E	-	EPS next Y	-1.58	Insider Trans	-35.81%	Shs Float	160.74M	Perf Month	29.68%
Enterprise Value	9.94B	PEG	-	EPS next Q	-0.74	Inst Own	85.70%	Short Float	13.68%	Perf Quarter	14.87%
Income	-667.97M	P/S	63.71	EPS this Y	-3.92%	Inst Trans	4.90%	Short Ratio	7.42	Perf Half Y	64.57%
Sales	127.42M	P/B	-	EPS next Y	47.19%	ROA	-77.18%	Short Interest	21.99M	Perf YTD	55.81%
Book/sh	-8.68	P/C	15.01	EPS next 5Y	-	ROE	-	52W High	42.20 1.32%	Perf Year	58.06%
Cash/sh	2.85	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-95.16%	52W Low	21.62 97.76%	Perf 3Y	556.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	92.24%	Volatility	2.86% 2.27%	Perf 5Y	34.75%
Dividend TTM	-	EV/Sales	78.05	EPS Y/Y TTM	-9.37%	Oper. Margin	-537.55%	ATR (14)	1.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.54	Sales Y/Y TTM	-41.71%	Profit Margin	-524.25%	RSI (14)	72.65	Recom	1.35
Dividend Gr. 3/5Y	- -	Current Ratio	4.57	EPS Q/Q	-346.73%	SMA20	11.57%	Beta	1.11	Target Price	60.33
Payout	-	Debt/Eq	-	Sales Q/Q	-44.76%	SMA50	17.67%	Rel Volume	0.62	Prev Close	42.17
Employees	730	LT Debt/Eq	-	Earnings	Apr 29 AMC	SMA200	37.06%	Avg Volume	2.96M	Price	42.76
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.13% 93.88%	Trades		Volume	307,290	Change	1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy	$75
May-21-21	Initiated	UBS	Buy	$80
Mar-22-21	Reiterated	Goldman	Buy	$83 → $91
Feb-22-21	Resumed	JP Morgan	Overweight	$78

Show Previous Ratings

Today 04:25AM	Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results (Insider Monkey)
Jun-11-25 07:54PM	BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright (Insider Monkey)
Jun-05-25 08:50AM	BridgeBio price target raised to $42 from $37 at BMO Capital (TipRanks)
Jun-02-25 07:30AM	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire)
May-23-25 03:21PM	Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
12:33PM	Loading…
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
04:24AM	BridgeBio's Acoramidis: A Breakthrough in ATTR-CM Treatment (Insider Monkey)
May-20-25 09:40AM	Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year? (Zacks)
07:30AM	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM (GlobeNewswire)
May-19-25 12:33PM	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study (GlobeNewswire)
May-14-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:27AM	BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug (Clinical Trials Arena)
06:50AM	Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday (Insider Monkey)
May-13-25 09:55AM	Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade (Zacks) -6.78%
07:30AM	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study (GlobeNewswire)
07:30AM	Loading…
May-12-25 07:30AM	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
07:30AM	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 (GlobeNewswire)
Apr-30-25 09:12PM	Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday (Insider Monkey) +5.33%
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
12:31PM	Q1 2025 BridgeBio Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
10:04AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:07AM	BridgeBio sales of new heart drug outstrip expectations (BioPharma Dive)
03:17AM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Apr-29-25 09:43PM	BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	BridgeBio Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
04:01PM	BridgeBio Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
11:39AM	BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
10:29AM	Loading…
10:29AM	UK MHRA authorises BridgeBios acoramidis for ATTR-CM (Pharmaceutical Technology)
Apr-28-25 07:18PM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
05:00AM	BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM (GlobeNewswire)
Apr-23-25 10:01AM	Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-22-25 11:14AM	BridgeBio: Early Signs Point To Blockbuster Revenues (Seeking Alpha)
07:30AM	BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET (GlobeNewswire)
Apr-11-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-25 10:00AM	Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM (GlobeNewswire)
Mar-29-25 04:12PM	Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 07:00AM	Beyonttra (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved in Japan to Treat ATTR-CM (GlobeNewswire)
Mar-24-25 07:30AM	BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions (GlobeNewswire) +7.05%
Mar-21-25 05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
04:00PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
Mar-17-25 04:01PM	BridgeBio Announces CFO Succession (GlobeNewswire)
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology) -5.42%
Feb-28-25 06:50AM	BridgeBio oncology spinout to go public in blank-check merger (BioPharma Dive)
Feb-26-25 11:56AM	BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
02:49AM	BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt (GlobeNewswire)
Feb-24-25 04:09PM	BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt (GlobeNewswire) -5.24%
Feb-23-25 03:07PM	Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	BridgeBio price target raised to $52 from $49 at Scotiabank (TipRanks)
Feb-21-25 05:13PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Feb-20-25 08:57AM	BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:55AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:49AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update (GlobeNewswire)
05:53AM	BridgeBios heart drug launch gets off to a fast start (BioPharma Dive)
Feb-13-25 04:01PM	BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 (GlobeNewswire) +10.58%
10:48AM	BridgeBio price target raised to $49 from $48 at Scotiabank (TipRanks)
Feb-12-25 06:40AM	EC grants marketing authorisation to BridgeBios ATTR-CM treatment (Pharmaceutical Technology)
Feb-11-25 09:21AM	BEYONTTRA (acoramidis), the First Near Complete TTR Stabilizer ( 90%), Approved by the European Commission to Treat ATTR-CM (GlobeNewswire)
06:38AM	Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK (BioPharma Dive)
Feb-08-25 08:46AM	Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 07:16PM	DHT, Evolve Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
07:16PM	DHT, Evolv Technologies, and More Stocks See Action From Activist Investors (Barrons.com)
Feb-04-25 08:58AM	Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday (Insider Monkey) +6.28%
Jan-29-25 04:00PM	Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? (Insider Monkey)
Jan-26-25 03:07AM	Why BridgeBio Pharma (BBIO) Is Skyrocketing Now (Insider Monkey)
Jan-23-25 06:42AM	Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? (Insider Monkey)
02:00AM	BridgeBios Neil Kumar on an underdog drug launch and wooing deal-hungry investors (BioPharma Dive)
Jan-15-25 08:58AM	Is BridgeBio Pharma, Inc. (BBIO) Among Tuesdays Top Gainers? (Insider Monkey)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily) +5.56%
10:00AM	Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? (Insider Monkey)
04:59AM	Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Jan-13-25 06:54PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) +15.99%
04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
11:00AM	BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones (GlobeNewswire)
Jan-08-25 07:30AM	BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-24 08:40AM	BridgeBio price target raised to $50 from $45 at Evercore ISI (TipRanks)
Dec-13-24 07:18AM	Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Dec-03-24 08:00AM	Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology (GlobeNewswire)
Nov-26-24 09:10AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
06:50AM	BridgeBio price target raised to $45 from $42 at BofA (TipRanks)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily) +16.10%
09:40AM	BridgeBio Soars After Drug Gets Nod in Rare Heart Condition (Bloomberg)
09:03AM	FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market (Benzinga)
04:38AM	FDA approves BridgeBios Attruby for ATTR-CM treatment (Pharmaceutical Technology)
Nov-22-24 07:11PM	Attruby (acoramidis), a Near Complete TTR Stabilizer ( 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients (GlobeNewswire)
02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-21-24 05:43PM	Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 02:44PM	BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market (Benzinga)
Nov-18-24 11:15AM	Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months (GlobeNewswire) -5.78%
05:30AM	BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia (GlobeNewswire)
Nov-12-24 08:39PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -5.74%
08:45AM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM
Kumar Neil	Chief Executive Officer	Feb 19 '25	Sale	36.14	31,543	1,140,024	211,718	Feb 19 08:48 PM
NEIL KUMAR	Director	Feb 19 '25	Proposed Sale	35.49	31,543	1,119,461		Feb 19 04:31 PM
BRIAN STEPHENSON	Officer	Feb 19 '25	Proposed Sale	35.49	4,148	147,213		Feb 19 04:31 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Proposed Sale	34.90	3,065,616	106,989,998		Jan 31 07:18 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Sale	34.90	3,065,616	106,989,998	22,055,375	Jan 31 07:18 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Option Exercise	17.00	68,000	1,156,000	161,758	Jan 30 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Sale	36.29	68,000	2,467,761	93,758	Jan 30 06:31 PM
Kumar Neil	Chief Executive Officer	Jan 28 '25	Sale	36.29	326,932	11,863,381	5,371,515	Jan 30 06:29 PM
Kumar Neil	Chief Executive Officer	Jan 29 '25	Sale	36.35	273,068	9,925,269	5,098,447	Jan 30 06:29 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 28 '25	Proposed Sale	36.67	600,000	22,002,000		Jan 28 04:18 PM
BRIAN STEPHENSON	Officer	Jan 28 '25	Proposed Sale	36.67	68,000	2,493,560		Jan 28 04:18 PM
Satvat Ali J.	Director	Dec 30 '24	Option Exercise	16.22	159,404	2,585,134	159,404	Dec 31 05:52 PM
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM
KKR Genetic Disorder L.P.	10% Owner	Sep 13 '24	Sale	25.75	5,800,000	149,350,000	25,260,971	Sep 17 06:44 PM
KKR Genetic Disorder L.P.	Affiliate	Sep 13 '24	Proposed Sale	26.95	5,800,000	156,310,000		Sep 13 05:04 PM
Kumar Neil	Chief Executive Officer	Aug 19 '24	Sale	24.69	27,389	676,256	4,897,443	Aug 20 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Aug 19 '24	Sale	24.69	4,155	102,590	85,192	Aug 20 06:27 PM
BRIAN STEPHENSON	Officer	Aug 19 '24	Proposed Sale	24.40	4,155	101,382		Aug 19 04:29 PM
NEIL KUMAR	Director	Aug 19 '24	Proposed Sale	24.40	27,389	668,292		Aug 19 04:27 PM

CDNA

Caredx Inc

BBIO

BridgeBio Pharma Inc

Upgrade your FINVIZ experience